GlaxoSmithKline Plans Vaccine Plant in Singapore
GlaxoSmithKline PLC (GSK, London, UK) will invest more than GBP102 million ($188 million) over the next four years in a vaccine manufacturing plant in Singapore.
GlaxoSmithKline PLC (GSK, London, UK, www.gsk.com) will invest more than GBP102 million($188 million) over the next four years in a vaccine manufacturingplant in Singapore.
The facility will be dedicated to the primary production of pediatricvaccines. Once operational, the facility will manufacture GSK'sconjugate vaccine, which provides protection against Streptococcus pneumoniae andnontypeable Haemophilus influenzae.
In 2005, GSK opened its Center for Research in Cognitive andNeurodegenerative Disorders in Singapore's Biopolis and also announcedplans to build a research and development pilot plant at its globalmanufacturing supply site in Jurong.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
